Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation.
We propose a method for selecting quality-of-life instruments for use in phase III trials using the convergent validity of patient responses collected in phase I and II clinical trials. Two generic and two disease-specific instruments were administered to patients with breast cancer undergoing peripheral blood progenitor cell mobilization and transplantation. They included the visual analog scale from the EuroQoL EQ5D instrument, the SF-36, the European Organization for Research and Treatment of Cancer (EORTC)-QLQ-C30, and the Functional Assessment of Cancer Therapy instrument. No single instrument was found to have superior convergent validity in all domains, but the EORTC-QLQ-C30 seemed to perform better than the SF-36.
University of Pennsylvania, USA.
H A
HA
Glick
E J
EJ
Shpall
C F
CF
LeMaistre
T J
TJ
McCarron
Z J
ZJ
Lu
M H
MH
Erder
J A
JA
Glaspy
D000328:Adult; D001943:Breast Neoplasms / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006305:Health Status Indicators; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000706:statistics & numerical data*; D006801:Humans; D016015:Logistic Models; D011788:Quality of Life; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires